Interleukin Genetics Reports Second Quarter 2008 Financial Results
WALTHAM, Mass., Aug. 13 MA-Interleukin-Genet
WALTHAM, Mass., Aug. 13 /PRNewswire-FirstCall/ -- Interleukin Genetics,
Inc. (Amex: ILI) today announced financial and business results for the second
quarter ended June 30, 2008.
The Company reported a net loss of $1.7 million, or $(0.05) per basic and
diluted common share, for the second quarter of 2008 compared to a net loss of
$2.0 million, or $(0.07) per basic and diluted common share, for the same
period last year.
Revenue for the second quarter of 2008 was $2.5 million compared to $2.4
million for the same period last year. The increase in revenue is primarily
attributable to an increase in consumer product revenue offset by a decrease
in genetic testing and contract research & development.
No comments:
Post a Comment